Caffetin COLDmax is applied across domains where additional symptomatic support is needed for individuals experiencing acute episodes of the common cold or influenza. The components are intended for symptomatic relief, focusing on managing symptoms across two main therapeutic areas: systemic discomfort and nasal obstruction.

Relief for Systemic Pain and Elevated Body Temperature

This medication is generally considered relevant for easing symptoms related to systemic imbalance, specifically managing mild to moderate pain across the body, including headache and generalized body aches, while also supporting the reduction of fever. It provides support that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms.

Addressing Nasal Congestion and Sinus Discomfort

The formulation is applied in addressing symptoms related to physical discomfort in the upper respiratory tract. It assists with reducing swelling in the nasal passages, which is relevant for easing nasal congestion (stuffy nose) and the resulting feeling of sinus pressure or fullness.

The core benefit is to provide support that helps ease the overall symptom burden. This therapeutic approach is commonly summarized as:

“The combination of analgesia and decongestion supports patients during difficult episodes by easing distress and contributing to improved comfort during periods of heightened symptoms.”

Quick Fact: Symptom Management Domains
Pain/Fever: Helps manage mild to moderate aches and supports fever reduction.
Nasal Blockage: Applied to address stuffy nose and sinus pressure.

Regulatory References

1. NIH DailyMed Drug Label for Acetaminophen/Phenylephrine

Eligibility Map: Who can and cannot use Caffetin COLDmax — official regulatory information

Populations for whom use is allowed (as stated in label):

• Adults and adolescents who are generally healthy.

Populations for whom use is contraindicated:

• Patients with severe hypertension or severe coronary artery disease.
• Patients with severe hepatic impairment or severe renal failure.
• Patients with hyperthyroidism, pheochromocytoma, or closed-angle glaucoma.
• Patients currently receiving or who have taken a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days.
• Individuals with a known hypersensitivity to Acetaminophen, Phenylephrine, or any excipients.

---

Age-related eligibility rules:

• Children under 12 years of age: Use is formally contraindicated or not recommended.
• Adults and Adolescents (12 years and older): Use is generally permitted.
• Older Adults (Geriatric): Use requires caution due to increased sensitivity to the effects of Phenylephrine.

Condition-specific eligibility rules:

• Pregnancy and Lactation: Use is generally contraindicated or not recommended.
• Conditional Use: Patients with mild to moderate hepatic or renal impairment, diabetes mellitus, or non-severe cardiovascular conditions are populations for whom use is permitted only with caution.

Connection to the Overall Eligibility Profile

Official regulatory documents define who can and cannot use Caffetin COLDmax by establishing absolute contraindications based on specific pre-existing severe cardiovascular and metabolic conditions or the concurrent use of MAOIs. Furthermore, eligibility is restricted by age, prohibiting use below 12 years, and by physiological status, formally classifying use in pregnant and breastfeeding women as contraindicated or not recommended.

Interactions with other medicines and products

This section details the officially documented interaction patterns for Caffetin COLDmax (Acetaminophen and Phenylephrine Hydrochloride), based strictly on government regulatory documents.

---

Key Regulatory Constraints

Category	Official Interaction Statement
Contraindicated Combinations	Use is prohibited with Monoamine Oxidase Inhibitors (MAOIs), which are certain drugs for depression or Parkinson’s disease. Use with other products containing Acetaminophen is also prohibited due to the risk of accumulation. Co-administration with other Sympathomimetic Amines is advised against.
Timing-Based Rules	Administration must be separated from MAOIs by a period of 14 days after discontinuation of the MAOI drug.
Pharmacodynamic Risk	Concomitant use with Antihypertensives may reduce the efficacy of the antihypertensive agent. Use with Tricyclic Antidepressants or Cardiac Glycosides is associated with an increased risk of cardiovascular effects.
Exposure Modification	A specific drug-drug interaction is documented: the co-administration of the two active components results in increased systemic exposure (bioavailability) of Phenylephrine.
Substance Restriction	Alcohol consumption of three or more drinks daily significantly increases the potential for Acetaminophen-related hepatotoxicity.

---

Official Interaction Structure Summary

The interaction profile is primarily defined by the absolute prohibition of co-administration with MAOIs and other acetaminophen-containing products due to severe risk classifications. The regulatory status documents that the combination itself alters exposure, specifically resulting in increased phenylephrine levels. The profile requires caution for use alongside Antihypertensives and notes that individuals with pre-existing high blood pressure or heart disease may be more vulnerable to the effects of the increased phenylephrine exposure. The structure of restrictions also includes mandatory timing separation for MAOI use and a constraint regarding chronic, heavy alcohol use.

Central Modulation of Pain and Thermoregulation

This domain involves Acetaminophen's targeted action within the Central Nervous System (CNS), primarily by inhibiting certain Cyclooxygenase (COX) enzymes and reducing the synthesis of Prostaglandins ( PGE2). This molecular action resets the hypothalamic thermoregulatory center, which leads to increased heat dissipation and a restoration of the physiological thermal set point, and simultaneously contributes to the elevation of the central nociceptive threshold.

---

Localized alpha1-Adrenergic Vascular Stimulation

This mechanism is driven by Phenylephrine Hydrochloride, which acts as an agonist on alpha1-adrenergic receptors located on the smooth muscle of blood vessels in the nasal and sinus mucosa. This direct sympathetic vascular stimulation initiates a cascade that leads to local vasoconstriction, a physiological change that reduces the localized volume of blood and tissue fluid in the nasal mucosa, leading to a mechanical reduction in mucosal tissue volume.

---

Dual Complementary Physiological Action

1. The combined effect arises from the simultaneous engagement of these two distinct mechanistic domains: one acting centrally to regulate systemic thermal/nociceptive processes, and the other acting peripherally to adjust localized vascular tone. This complementary action independently modulates systemic thermal/nociceptive regulation and localized vascular tone.

How to Use Caffetin COLDmax

This section details the high-level administration and dosing principles for the Acetaminophen and Phenylephrine Hydrochloride combination.

---

Administration Guidelines

Instruction Entity	Statement
Route of Administration	The medication is intended for oral use.
Standard Single Dose	One sachet (powder for oral solution) containing 1000 mg Acetaminophen and 12.2 mg Phenylephrine Hydrochloride.
Minimum Dosing Interval	Doses must be separated by an interval of 4 to 6 hours.
Maximum Daily Dose	Do not exceed 4 sachets over any 24-hour period.

---

Preparation and Use Context

Caffetin COLDmax powder must be prepared immediately before ingestion. The full contents of one sachet are dissolved in a cup of warm (not boiling) water. The resulting solution may be sweetened if desired. The dosing schedule is as-needed (intermittent use) and is for short-term use only to manage acute symptoms. Should symptoms worsen or persist beyond a specified short duration, continuation of use should be ceased.

Population-Specific Rules

Use of this product is not approved for pediatric patients under 16 years of age. Adolescents 16 years and older follow the adult regimen. No specific dose adjustment is required for older adults when using this combination product. These administration guidelines describe the protocol for preparation and intake.

Caffetin COLDmax: Overview of Clinical Evidence

The formulation of Caffetin COLDmax typically includes two active ingredients: Paracetamol (also known as Acetaminophen) and Phenylephrine hydrochloride. Clinical research supports the use of these components individually and in combination for the symptomatic management of the common cold and influenza-like illnesses.

Evidence for Component Activity

• Paracetamol (Acetaminophen): Numerous randomized controlled trials (RCTs) confirm the role of paracetamol as an analgesic and antipyretic agent. In studies involving participants with upper respiratory tract infections, paracetamol administration was associated with a reduction in fever and a mitigation of minor aches and pains (such as headache and muscle discomfort) when compared to placebo. It addresses the systemic symptoms often associated with colds.

• Phenylephrine: This ingredient is classified as a sympathomimetic amine with decongestant properties. Clinical evidence indicates that phenylephrine, when administered orally, may contribute to the temporary relief of nasal and sinus congestion. Its action is thought to result in the constriction of blood vessels in the nasal passages, which can lessen swelling and facilitate breathing.

Combination Studies

While specific, dedicated clinical trials for a fixed combination of paracetamol and phenylephrine are numerous across different regulatory bodies, the general scientific consensus supports the co-administration of agents that address different symptom pathways. Combination products are typically assessed in double-blind, placebo-controlled environments against criteria such as total symptom scores or individual symptom severity (e.g., headache, fever, nasal congestion) over a short-term period. These studies observe the effect of the multi-component formulation on the overall experience of cold and flu symptoms in adult populations.

Common questions about Caffetin COLDmax (FAQ)

Q: Why do some people report feeling nervous or jittery after taking this medicine?

Official product information lists nervousness and insomnia (difficulty sleeping) as possible side effects. These reactions are associated with the phenylephrine component, which has sympathomimetic (stimulating) effects.

Q: What does the official documentation say about the frequency of stomach upset with Caffetin COLDmax?

The regulatory documentation states that nausea (feeling sick) is a potential side effect classified under Gastrointestinal Disorders. General guidance for the medicine's active ingredients sometimes suggests that separating intake from food, or taking it with food, may be considered.

Q: What are the signs of a hypersensitivity reaction as described in the official documents?

Regulatory labels outline potential signs of an allergic reaction. These may include the development of a rash or hives, or swelling of the face, lips, tongue, or throat. If any signs of hypersensitivity are observed, official guidance describes the need to discontinue use.

Q: What is the expected period of support or relief after taking a dose?

The dosing schedule requires a period of 4 to 6 hours between doses, which is the minimum recommended interval before the next dose may be considered. Pharmacokinetic data indicates that the active ingredients generally reach their maximum concentration in the body within 10 to 60 minutes of being taken.

Q: Has Caffetin COLDmax been the subject of recent clinical studies?

The symptomatic use of the product is supported by clinical studies involving its active components and combination products. However, the regulatory documentation does not typically specify the exact dates or recency of all underlying clinical trials that confirm its efficacy.

Q: Does the medicine contain ingredients that might cause issues for individuals with allergies to certain dyes or fillers?

Regulatory documents list all excipients (non-active ingredients) in the product, such as sucrose and aspartame. The presence of these excipients requires that individuals with known hypersensitivities review the full list of ingredients.

Q: Is experiencing drowsiness or tiredness a known possibility when taking Caffetin COLDmax?

Official labeling includes Central Nervous System (CNS) effects like dizziness and insomnia (difficulty sleeping). While the product is not typically associated with specific warnings for drowsiness, official information indicates that caution may be necessary if CNS side effects are experienced.

Q: Does Caffetin COLDmax interact with any common blood thinning medicines?

Official warnings advise caution regarding blood thinning medicines. The regulatory label notes the importance of consulting a healthcare professional before use if the person is taking drugs like warfarin, due to potential interactions with the acetaminophen component.

Q: How quickly do the effects of Caffetin COLDmax usually start for most people?

Pharmacokinetic studies indicate that the maximum concentration of the active ingredients in the body is generally reached within 10 to 60 minutes after taking the medicine. This time frame may align with the onset of symptomatic relief.

Q: What is the described role of caffeine in a cold and flu medicine formulation?

The official product composition for Caffetin COLDmax does not list caffeine as an active ingredient. The product only contains the two primary active components: Paracetamol (Acetaminophen) and Phenylephrine Hydrochloride.

Q: What official guidance exists about driving or operating machinery while using Caffetin COLDmax?

Official guidance addresses the need for caution with driving or operating machinery. This is necessary if the user experiences any side effects, such as dizziness or insomnia, that could potentially impair their ability to perform these tasks safely.

How to Store and Dispose of Caffetin COLDmax?

The storage and disposal of Caffetin COLDmax are governed by regulatory requirements to ensure product quality and environmental safety.

Storage Requirements

The medicine must be stored at a temperature below 25°C and kept out of the reach of children. The tablets should not be removed from the original blister packaging in advance. Do not use the product after the expiry date (EXP) printed on the carton and blister, as this date dictates the shelf-life of the medication.

Disposal Instructions

Official guidelines state that medicines should not be disposed of via wastewater or household waste. To discard unused or expired Caffetin COLDmax, the user is instructed to ask a pharmacist for the proper method of disposal, ensuring compliance with local environmental regulations.